Abstract
Aim:Cancer antigen 72–4 (CA 72–4) is an established tumor marker in ovarian cancer. We evaluated a new solid-phase ELISA (DRG TM-CA 72–4 ELISA).Materials & methods:Repeated measures of test samples and controls were performed to evaluate reliability and reproducibility. Afterward, we performed analyses on the sera of 150 patients with primarily diagnosed ovarian cancer. Results were compared with those of the Cobas CA 72–4 kit. Results were correlated with clinical patient data.Results:Results of the DRG TM-CA 72–4 ELISA were reproducible with acceptable deviations within measures, and the measured CA 72–4 serum concentrations were well in accordance with the references. High concentrations were significantly associated with grading, tumor stage and tumor residuals after surgery.
Highlights
Our data suggest that the DRG TM-CA 72-4 ELISA may be used in clinical practice in ovarian cancer patients as it shows comparable result to the frequently used Cobas assay
Our results show that the DRG TM-CA 72-4 ELISA is reliable and precise and may be used in clinical practice
Taken together, our data suggest that the DRG TM-CA 72-4 ELISA may be used in clinical practice in ovarian cancer patients as it shows comparable results to the frequently used Cobas assay
Summary
Cancer antigen 72–4 (CA 72-4) is an established tumor marker in ovarian cancer. The aim of the present study was to validate the newly developed solid-phase DRG TM-CA 72-4 ELISA (DRG Instruments GmbH, Marburg, Germany).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
